LOXL2 and Hepatic fibrosis: The LOXL2-neutrolazing monoclonal antibody AB0023 exerts the inhibitory effect of LOXL2 by targeting its SRCR domain [93]; whereby, AB0023 has been shown to effectively alleviate liver fibrosis in mouse models induced by CCl4 [94], by thioacetamide (TAA), and using Mdr2−/− plus 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) [8].